Kornimate/medical-research-clean huggingface dataset:
acusleep in mild traumatic brain injury (tbi)

Conditions: Brain Injuries, Traumatic; Sleeplessness

Summary: objective: to evaluate real acupuncture, as compare to sham acupuncture, in improving persistent sleep difficulties in veterans with mild traumatic brain injury (mtbi) design: randomized, blinded, sham-controlled clinical trial setting: outpatient clinic at a major va medical center in southeast usa participants: sixty veterans aged 24-55 (mean 40) with history of mtbi at least 3-month and beyond, suffering from sleep difficulties refractory to regular care and sleep education, as indicated by a global pittsburgh sleep quality index (psqi) score of 14.25 + 3.23 pre-intervention (baseline). they were randomized into 2 groups, real acupuncture versus sham acupuncture, and stratified by post-traumatic stress disorder (ptsd) diagnosed by ptsd checklist - military version (pcl-m). intervention: real or sham acupuncture with both standardized and individualized acupoints selection. all subjects were informed that the treatments, if effective, may improve symptoms such as pain, anxiety or depression other than sleep; real acupuncture may not be effective in some individuals, and sham acupuncture may as well be effective by mind-body interactions. outcome measures: primary outcome measure was global psqi score change after intervention as compared to baseline. secondary outcome measure was wrist-actigraphy sleep latency, sleep efficiency, wake after sleep onset (waso), and sleep duration. ptsd was analyzed as a co-variant.


Eligibility criteria:
inclusion criteria: * age: 18 to 55; and, * meeting the diagnosis criteria for mild traumatic brain injury as listed above at the time of injury; and, * at or over 3 months post injury; and, * with untreated sleep complaints (pittsburgh sleep quality index \[psqi\] \> 8, sleep difficulties at least 4x per week in the past month, average sleep duration of 6 hours or less); and, * has the capacity to give informed consent. * agree to attend 13 clinic visits exclusion criteria: * same sleep complaints present prior to traumatic brain injury; or, * diagnosis of obstructive sleep apnea (osa) by prior sleep study; or, * with a non-daytime work-schedule; or, * with prior acupuncture experience for the treatment of sleep difficulties or with acupuncture treatment within 3 months; or, * history of bleeding diathesis or currently on anticoagulation with international normalized ratio (inr) over 2.5; or, * severe depression with beck depression score of 29 and above; or, * moderate and severe alcohol users. * does not have a permanent address

Keywords: acupuncture sleep traumatic brain injury
adc in assessing femoral tunnel position

Conditions: ACL Injury

Summary: to examine the consistency between postoperative ct scan and intraoperative arthroscopic measurement in evaluating femoral tunnel position for anterior cruciate ligament （acl）reconstruction，both using the apex of the deep cartilage（adc）as the marker.

the position of the center of femoral tunnel was decided in the complete femoral stub. then the length from the adc to the anterior cartilage margin（l1）and to the center of femoral tunnel（l1），as well as the center to the distal cartilage margin（d1）were measured under arthroscopy and on post-operative ct scan（l2，l2 and d2）. moreover，p1 and p2 were calculated through l1/l1 and l2/l2.

Eligibility criteria:
inclusion criteria: * adults aged 18-55 who need anterior cruciate ligament reconstruction exclusion criteria: * volunteers unsuitable for anterior cruciate ligament reconstruction

Keywords: femoral tunnel apex of the deep cartilage（adc）
impact of elka, the toolset for food exchanges calculation on metabolic control in pediatric diabetic patients.

Conditions: Type 1 Diabetes Mellitus

Summary: elka system is an advanced toolset which helps performing calculation of carbohydrate (cho) and fat/protein (fp) exchanges. it consists of elka software including database of various meals and nutrients and elkaplus digital kitchen scale transmitting weight of products in a real-time to a computer via universal serial bus (usb) port. after choosing the name of particular product from the list, the program gives precise information about the amount of cho and fp exchanges in serving. the aim of the study is to investigate the benefit of using elka toolset in comparison with standard method of cho and fp counting on metabolic control in type 1 diabetic children.

a randomized, controlled, parallel, open-label 26-week clinical trial will be conducted in 106 pediatric patients with type 1 diabetes mellitus (dm). patients will be randomly assigned into two groups: the group a (n=53) using elka system for food exchange counting and the group b (n= 53) using standard method. the glycated hemoglobin levels will be measured in both groups at the beginning, after 3 and 6 months of observation. the group a also will be asked about the frequency of using the toolset. we will also assess secondary endpoints (mentioned below).

Eligibility criteria:
inclusion criteria: * age under 18 y * confirmed dm type 1 * dm for \> 1 year * hba1c ≤ 10% * computer meeting elka system minimum requirements * kitchen arrangement providing enough space for computer with elka system * written informed consent exclusion criteria: * dm other than type 1 * duration of diabetes \< 1 year * conventional insulin therapy * nutritional disorders * celiac disease recognized in less than 4 months before inclusion * preceding experience with software * expected 21 or more consecutive days pausing in system usage * any medical condition, which, in the opinion of the investigator, would interfere with the evaluation of the subject

Keywords: diabetes diet control toolset food exchanges cho fp
lymph node mapping and sentinel lymph node identification in patients with stage ib1 cervical cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage I Cervical Cancer

Summary: this clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage ib1 cervical cancer. diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.

objectives: i. determine the sensitivity of the sentinel lymph node in the determination of lymph node metastases, using preoperative or intraoperative lymphatic mapping, in patients with stage ib1 cervical cancer. ii. determine the false-negative predictive value of the sentinel lymph node in the determination of lymph node metastases in these patients. outline: this is a multicenter study. patients receive radiolabeled technetium tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.

Eligibility criteria:
inclusion criteria: * diagnosis of carcinoma of the cervix of 1 of the following cellular types: * squamous cell carcinoma * adenocarcinoma * adenosquamous cell carcinoma * stage ib1 disease (no greater than 4 cm) * no unequivocal evidence of metastases * adequate surgical candidate * no known allergy to triphenylmethane compounds * no prior pelvic irradiation * no prior retroperitoneal surgery * more than 4 weeks since prior cold knife or loop electrosurgical excision procedure (leep) cone biopsy * prior cone biopsy allowed provided current disease is stage ib1
a study of balovaptan in adults with autism spectrum disorder with a 2-year open-label extension

Conditions: Autism Spectrum Disorder

Summary: this study will evaluate the efficacy, safety, and pharmacokinetics of 10 mg of oral administration balovaptan once a day (qd) compared with matching placebo in adults (18 years and older) with autism spectrum disorder (asd).


Eligibility criteria:
inclusion criteria: * subject meets the dsm-5 criteria for asd for an autism diagnosis and is confirmed using ados-2 criteria * srs-2, proxy version, total t-score \>=66 at screening * a full scale iq score \>=70 on the wasi®-ii * subject has an appropriate study partner, in the opinion of the investigator * for women of childbearing potential: agreement to remain abstinent or use a contraceptive method with a failure rate of \<1% per year during the treatment period and for at least 28 days after the last dose of study drug * treatment with permitted medications (at a stable dose for 12 weeks before screening) and behavioral therapy regimens (regimens stable for 6 weeks before screening), with the intent that such treatments remain stable throughout the study and with no expected changes before the week 24 visit exclusion criteria: * pregnancy or breastfeeding, or intention to become pregnant during the study * previous initiation of new or major change in psychosocial intervention within 6 weeks prior to screening * unstable or uncontrolled clinically significant affective or psychotic disorders and/or neurologic disorder that may interfere with the assessment of safety or efficacy endpoints * substance use disorders during the last 12 months * significant risk for suicidal behavior, in the opinion of the investigator * epilepsy or seizure disorder considered not well controlled within the past 6 months or changes in anticonvulsive therapy within the last 6 months * clinical diagnosis of peripheral neuropathy * within the last 2 years, unstable or clinically significant cardiovascular disease * uncontrolled hypertension * unexplained syncopal episode within the last 12 months * confirmed elevation above upper limit of normal of ck-mb, high sensitivity cardiac troponin t, cardiac troponin i, and/or n-terminal pro b-type natriuretic peptide * positive serology results for hepatitis b surface antigen (hbsag), hepatitis c virus (hcv) antibody, or human immunodeficiency virus (hiv) 1 or 2 * history of coagulopathies, bleeding disorders, blood dyscrasias, hematological malignancies, myelosuppression (including iatrogenic), or current major bleeding event * concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or what would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study * confirmed clinically significant abnormality in parameters of hematology * confirmed clinically significant abnormality in parameters of clinical chemistry, coagulation, or urinalysis * medical history of malignancy, if not considered cured
doppler ultrasound in rewarming after targeted control management in cardiac arrest

Conditions: Cardiac Arrest; Doppler Ultrasound

Summary: the aim of the study is to describe cbf modifications during rewarming after targeted temperature management in cardiac arrest patients


Eligibility criteria:
inclusion criteria: major cardiac arrest targeted temperature management exclusion criteria: gcs\>8 after cardiac arrest neurologic cause of cardiac arrest
curcumin-simvastatin-edta in the treatment of periodontitis

Conditions: Periodontitis

Summary: among the root conditioning materials is the ethylenediaminetetraacetic acid (edta). edta exposes the collagen fibers on dentin surfaces and also enhances early cell colonization. statins have an anti-inflammatory effect, inhibit the bone resorption and stimulate the bone formation. curcumin is effective in preventing periodontal disease destruction by targeting both bacteria and host inflammatory cells. curcumin has anti- inflammatory, antioxidant, anticarcinogenic, antiviral, and antimicrobial functions. this study will be carried out to examine the effect of simvastatin-curcumin paste following edta root surface etching when used in conjunction with open flap debridement treating deep periodontal pockets (suggesting that it may have positive effect)

the present study entailed thirty patients having stage ii or stage iii, grade a periodontitis with 30 intrabony defects. patients were divided into three groups; group i was subjected to open flap debridement only. group ii was subjected to open flap debridement followed by application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin). group iii was subjected to open flap debridement followed by 24% edta root surface etching and application of curcumin-simvastatin paste (2% curcumin and 1.2% simvastatin).clinical parameters including plaque index, sulcus bleeding index, probing depth and clinical attachment level were recorded pre-surgical. moreover, radiographic examination was performed by cone beam computed tomography (cbct) just before the surgery . vertical bone defects were exposed by full thickness mucoperiosteal flap following intrasulcular incision and thorough debridement was performed. group ii received local application of curcumin-simvastatin paste .group iii received curcumin-simvastatin paste after debridement and 24 % edta. the same initial clinical parameters were recorded three and six months postoperatively. radiographic measurements were recorded six months post surgically.

Eligibility criteria:
inclusion criteria: * patient suffering at least a single posterior 2-3 wall periodontal pocket of depth ≥ 5 mm, attachment loss ≥3 mm, intrabony component ≥3 mm, plaque index ≤1 (sillness and loe, 1964) and sulcus bleeding index ≤1 (mühlemann \& son, 1971). all these criteria were determined after phase i conventional periodontal therapy. * systemically healthy as evidenced by burket's oral medicine health history question questionnaire (glick et al., 2008). * patients available during follow-up periods exclusion criteria: * smoking * patient unwilling to comply with periodontal hygienic instructions * patients under any long-term chronic medication * vulnerable individuals

Keywords: periodontitis curcumin simvastatin edta
effect of crestor on lipoprotein metabolism in humans

Conditions: Hypercholesterolemia

Summary: the objective of this research is to understand how crestor can effectively reduce the levels of the bad cholesterol, ldl, in blood. it is hypothesized that with a low dose, crestor will facilitate the rate of removal of ldl from the blood. at the higher dose, the increased potency of crestor is explained by a reduction in the production of ldl by the liver.

crestor has been demonstrated to be effective in reducing plasma ldl by 20 to 60% in a dose dependent fashion. while the primary mechanism of action of this class of agents is the increase in the expression of ldl receptor resulting in accelerated clearance of ldl, the increase potency of crestor in comparison to other statins may suggest other mechanisms. we propose to study the rate of incorporation of deuterated labeled leucine into vldl apob and ldl apob and to determine the effect of two doses of crestor (5 mg/day and 40 mg/day) on the production and clearance of apob. participants will be admitted to the general clinical research center on three occasions (4 days, 3 nights per admission) for these metabolic studies. this is an open-label study design to reflect usual care with the first admission taking place while the participant is not on any lipid-lowering therapy. the second admission will occur after a minimum of 6 weeks on the low dose (5mg/day). the dose will be increased to 40 mg/day at the time of discharge and the third admission will occur after a minimum of 6 weeks on the higher dose. a secondary objective of this study is to examine the rate of production and clearance of apoa-i, the major protein in hdl, at the 2 doses of crestor. in addition to a reduction in ldl, crestor has also been reported to result in a characteristic dose-dependent increase in hdl. the mechanism of this increase is not understood.

Eligibility criteria:
inclusion criteria: * tg between 200 and 400 mg/dl * ldlc between 160 and 250 mg/dl * hdlc between 30 and 50 mg/dl for men and 40-65 mg/dl for women * lp(a) less than 30 mg/dl * age between 50 and 75 years exclusion criteria: * current lipid-lowering therapy, * primary hypertriglyceridemia (tg\>400 mg/dl), * high hdl (hdl\>70), * high lp(a), greater than 30 mg/dl * presence of beta-vldl on agarose electrophoresis, * current use of immunosuppressive agents, * hormone replacement therapy for women * history of cancer, active liver disease or hepatic dysfunction (ast or alt 1.5 x uln (upper limit of normal), * excessive consumption of alcohol, and recent history of drug abuse.

Keywords: hypercholesterolemia hmg coa reductase inhibtors tracer kinetics apolipoproteins
ex vivo laboratory assays application for therapy tailoring in patients with severe bleeding disorders

Conditions: Severe Hemophilia

Summary: therapy of patients with severe hemophilia (including hemophilia with inhibitors) and other severe bleeding disorders could be monitored and guided based upon special clotting assays , eg thrombin generation and thromboelastography. in this study blood sampled from patients with bleeding disorders will be evaluated applying ex- vivo spiking assays with various coagulation concentrates to potentially address the feasibility of replacement /bypass agents/ combined therapy for future bleeding episodes. patients that will be further treated by any regimen potentially suggested (as standard care- not within trial) will be thereafter followed , including repeated lab studies to assess the impact of therapy upon hemostasis.


Eligibility criteria:
inclusion criteria: * informed consent * validated coagulation disorder exclusion criteria: * not consenting to participate * multiple coagulopathies and comorbidities

Keywords: response to various potential therapies as managed by lab assays
association between genetic polymorphisms and type 2 asthma in children

Conditions: Asthma in Children; Genetic Disease; Inflammation

Summary: to further understand the role of gene single nucleotide polymorphism (snp) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (snp), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. to provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.

type of study: this was a prospective, randomized case-control design.to investigate the role of genetic single nucleotide polymorphisms (snps) in children with type 2 asthma, and the effects of snps on type 2 inflammatory markers and pulmonary function indicators. methods: children with asthma who were treated at our pediatric respiratory specialty clinic and who met the criteria for type 2 inflammation were included in the case group (type 2 inflammation was considered to be present if any of the following conditions were present: fraction of exhaled nitric oxide(feno)≥20ppb；blood eosinophilcount≥350/ul；percentage of sputum eosinophils\>3%; asthma is caused by inhaled allergens.). the control group is healthy children who underwent physical examination. to compare the differences of single nucleotide polymorphisms (snps) between children with type 2 asthma and healthy children, and to explore the risk factors of type 2 asthma. the differences of indicators between different genotypes were compared, including type 2 inflammation indicators (including fraction of exhaled nitric oxide(feno)、blood eosinophil count、percentage of sputum eosinophils and serum total immunoglobulin e) and pulmonary function indicators(forced expiratory volume in one second(fev1)、forced vital capacity(fvc)、ratio of forced expiratory volume in one second to forced vital capacity(fev1/fvc) and peak expiratory flow(pef)).

Eligibility criteria:
inclusion criteria: 1. all children with asthma diagnosis accord with the gina in 2023 edition; 2. other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies; 3. in front of the hospital 2 weeks without antibiotics, systemic hormone medication history; 4. there were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc. exclusion criteria: 1. children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission; 2. children with primary immunodeficiency disease; 3. the children and their families failed to cooperate or refused the experimental observation.

Keywords: cytokines single nucleotide polymorphism type 2 inflammation ashtma susceptibility
heated circuit on sore throat

Conditions: General Anesthesia

Summary: this investigation is planned to compare the incidence and severity of postoperative sore throat according to the use of heated breathing circuit in patients undergoing endotracheal intubation for general anesthesia.


Eligibility criteria:
inclusion criteria: * asa i-iii * patients scheduled for general anesthesia with endotracheal intubation exclusion criteria: * difficult airway * mallampatti scores greater than 2 * recent sore throat * cervical spine disease * recent upper respiratory infection * recent analgesics * history of head and neck surgery * friable teeth * multiple intubation attempts

Keywords: pharyngitis intubation heat